Pictured (l.-r.) at the recent check presentation are Allison Reiss, MD, Head of the Inflammation Section at Winthrop; Josie DiChiara, Senior Vice President of External Relations, Alzheimer's Foundation of America (AFA); Mark Stecker, MD, PhD, Chairman of the Department of Neurosciences at Winthrop; Bert Brodsky, Chairman of the Board at AFA; Iryna Voloshyna, PhD, Research Associate at Winthrop; and Charles J. Fuschillo, Jr., AFA's President and CEO.
The grant will assist researchers Allison Reiss, MD, Head of the Inflammation Section of the Winthrop Research Institute, and Mark Stecker, MD, PhD, Chairman of the Department of Neurosciences at Winthrop, along with their team in conducting an innovative study called "Platelet-Rich Plasma in the Study of Alzheimer's Pathophysiology."
There are significant systemic abnormalities in patients with AD, according to Dr. Reiss
Platelets from patients with AD produce too much amyloid, and studies have shown that levels of secreted amyloid are high even in the blood of patients with only mild cognitive impairment.
"The study is based on the belief that Alzheimer's is not just going on in the brain, but that it is a whole body disease," said Dr. Reiss
This research has potential in both biomarker development-diagnosing who is at risk early on-and developing drug therapies to treat AD.
"If you have faulty machinery for amyloid in the brain, you most likely have faulty machinery in your platelets," added Dr. Reiss